Shaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

When Shaun Noorian encountered what he felt was a poorly ran process, as an engineer, he built something better. Now, he runs one of the nation's largest compounding pharmacies that's at a pivotal time for growth.

Headquartered in Houston, Empower Pharmacy is opening two new facilities locally — one debuts later this year and the other in 2022. Ahead of this milestone for his company, Noorian joined InnovationMap for a Q&A about how he decided to start his company and how he's grown it from a small office to two 85,000-square-foot facilities — as well as how Houston has been a big part of his company's success.

InnovationMap: Why did you decide to form Empower Pharmacy?

Shaun Noorian: I initially started Empower Pharmacy as a patient that was frustrated with the medication that I was receiving from a local compounding pharmacy in Houston.

I'd been working as a hydraulic fracturing field engineer at Schlumberger after graduating from college with a degree in mechanical engineering and was injured after several months on the job. I hemorrhaged three of my lower vertebrae and was put into physical therapy to try and fix my back. One of the doctors that was treating me noticed that I was very skinny for my age. I was probably 25 years old at the time. He decided to test my blood for the hormone testosterone, which is responsible for muscle growth and many other important factors in both men and women. The test determined that I had the testosterone level of an elderly man. The doctors sent me to Baylor College of Medicine for MRI blood tests, and they determined that I had a pituitary disorder and that I couldn't create the hormones responsible to tell my body to create testosterone. They put me on testosterone replacement therapy and it completely changed my life. Being testosterone deficient my entire life, I didn't realize what normal should be.When I was put on the medication, it was like a new lease on life. And I became very interested in the medication that I was taking, and how it worked. I studied everything I could. I was getting my medications from a local compounding pharmacy here in Houston, and I wasn't very satisfied with the quality of the service or the costs. Getting these medications was a very large percentage of my, what I was living off of. I couldn't figure out why this medication was so expensive when it cost just a few cents to make.

IM: How did you turn that passion into a business?

SN: I guess like most engineers, I decided I wanted to build — to make my own pharmacy. And make my own drugs and offer them to patients in a manner that I would want to it be from a patient's perspective when dealing with the compound pharmacy. I leased about 100 square feet in the back of the doctor's office. I pretty much converted one of his exam rooms and started my pharmacy there. I hired a pharmacist and did all the technician duties myself. I wanted to apply the patient experience that I would've wanted.

Slowly but surely, patients and prescribers around the area were very happy with the level of service and quality that they were receiving from our pharmacy. And we would get more requests through simple word of mouth and reputation. We grew pretty quickly out of that space and then built out a 1,500-square-foot space in a shopping center a couple of years later.

Following several more expansions and new locations throughout the years, we're now gearing up to open our new facility (7601 N. Sam Houston Parkway W., near the intersection of Highway 249 and Beltway 8), which will be the most advanced compounding pharmacy ever built. It has a lot of automation, and utilizes the same processes and equipment that Big Pharma uses to make their drugs. We're trying to better the system and continue to bring automation into the compounding industry so we can continue to scale and set a standard for the rest of the industry.

IM: What sets your business apart from what else is out there?

SN: We're a pharmacy that wants to do everything in house. We want to integrate our supply chain, and that means removing low value middleman from the health care ecosystem and streamline the medical distribution process. This means being the manufacturer, distributor, and regional pharmacy all in one, so we can really control our supply chain and integrate it. And at the same time, we can really be able to control and customize the consumer experience for both our patients and prescribers in a way that we would want. It's been a lot of fun being able to create your own healthcare ecosystem and building software for that your for patients that I'd want to use.

I'm an engineer. It's more fun talking about my equipment than anything else.

If you walk into a Walgreens, it's a simple repackaging operation. You're taking pills from a big bottle and putting them in a smaller bottle. What differentiates us from them and what's unique about this facility is that it's really built the same way as traditional pharmaceutical manufacturing is built using the same exact processes, systems, layout, etc.

We create our own purified water. We create our own clean, dry compressed air. We create our own clean steam that we use in our compounding processes, which are built to CGMP — current good manufacturing practices — specifications. We adopt a lot of those processes into the facility, and we built the facility around those standards that the FDA requires.

IM: You mentioned a new facility — but Empower is actually opening two new facilities within a year of each other. Tell me about those.

SN: Each facility is a mirror of each other — they are both 85,000 square feet. The one that's opening this year is going to be a pharmacy, so it'll just be dealing with patients. The next one is going to be licensed with the FDA and will work with larger institutions, selling medications in bulk for office use to institutions, hospitals, clinics, and prescribers. They will administer those medications to their patients in office. It's our way of being able to integrate that supply chain, so we can be that one-stop shop. So, physicians don't have to go to different vendors to source their medications — we can be an all-encompassing partner and vendor for them to source all their medical needs.

IN: How else are you expanding your business model?

SN: We've always concentrated on — since the inception of the company — quality, service, and cost. And we're always working to figure out how to increase quality, how to decrease costs, and how to make it easier and more convenient for our customers to use us. Some projects that we've been working on that are set to launch in the next few years is building out our own API – application programming interface – so that our telemedicine and other clients that are using electronic versions of health care record software can easily interface with our systems and vice versa.

IM: How has Houston been for you as a home base for Empower?

SN: I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation. It's really just a lot of luck of being in Houston. I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow. Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs. Having a diverse workforce has been integral in our growth. Also, having two schools of pharmacy in our backyard has also helped.

There's a reason why, as we grow, we always stay in Houston. It doesn't make sense for us to go anywhere else. This is a great city and a great state to do business.

IM: Are you hiring?

Oh, we're always hiring. I think we currently have around 50 positions open and there's everything from pharmacy operations, all the way to manufacturing and marketing to sales, logistics, legal, you name it.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston-based lunar mission's rocky landing and what it means for America's return to the moon

houston, we have a problem

A private U.S. lunar lander tipped over at touchdown and ended up on its side near the moon’s south pole, hampering communications, company officials said Friday.

Intuitive Machines initially believed its six-footed lander, Odysseus, was upright after Thursday's touchdown. But CEO Steve Altemus said Friday the craft “caught a foot in the surface," falling onto its side and, quite possibly, leaning against a rock. He said it was coming in too fast and may have snapped a leg.

“So far, we have quite a bit of operational capability even though we’re tipped over," he told reporters.

But some antennas were pointed toward the surface, limiting flight controllers' ability to get data down, Altemus said. The antennas were stationed high on the 14-foot (4.3-meter) lander to facilitate communications at the hilly, cratered and shadowed south polar region.

Odysseus — the first U.S. lander in more than 50 years — is thought to be within a few miles (kilometers) of its intended landing site near the Malapert A crater, less than 200 miles (300 kilometers) from the south pole. NASA, the main customer, wanted to get as close as possible to the pole to scout out the area before astronauts show up later this decade.

NASA's Lunar Reconnaissance Orbiter will attempt to pinpoint the lander's location, as it flies overhead this weekend.

With Thursday’s touchdown, Intuitive Machines became the first private business to pull off a moon landing, a feat previously achieved by only five countries. Japan was the latest country to score a landing, but its lander also ended up on its side last month.

Odysseus' mission was sponsored in large part by NASA, whose experiments were on board. NASA paid $118 million for the delivery under a program meant to jump-start the lunar economy.

One of the NASA experiments was pressed into service when the lander's navigation system did not kick in. Intuitive Machines caught the problem in advance when it tried to use its lasers to improve the lander's orbit. Otherwise, flight controllers would not have discovered the failure until it was too late, just five minutes before touchdown.

“Serendipity is absolutely the right word,” mission director Tim Crain said.

It turns out that a switch was not flipped before flight, preventing the system's activation in space.

Launched last week from Florida, Odysseus took an extra lap around the moon Thursday to allow time for the last-minute switch to NASA's laser system, which saved the day, officials noted.

Another experiment, a cube with four cameras, was supposed to pop off 30 seconds before touchdown to capture pictures of Odysseus’ landing. But Embry-Riddle Aeronautical University’s EagleCam was deliberately powered off during the final descent because of the navigation switch and stayed attached to the lander.

Embry-Riddle's Troy Henderson said his team will try to release EagleCam in the coming days, so it can photograph the lander from roughly 26 feet (8 meters) away.

"Getting that final picture of the lander on the surface is still an incredibly important task for us,” Henderson told The Associated Press.

Intuitive Machines anticipates just another week of operations on the moon for the solar-powered lander — nine or 10 days at most — before lunar nightfall hits.

The company was the second business to aim for the moon under NASA's commercial lunar services program. Last month, Pittsburgh's Astrobotic Technology gave it a shot, but a fuel leak on the lander cut the mission short and the craft ended up crashing back to Earth.

Until Thursday, the U.S. had not landed on the moon since Apollo 17's Gene Cernan and Harrison Schmitt closed out NASA's famed moon-landing program in December 1972. NASA's new effort to return astronauts to the moon is named Artemis after Apollo's mythological twin sister. The first Artemis crew landing is planned for 2026 at the earliest.

3 female Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Emma Konet, co-founder and CTO of Tierra Climate

Emma Konet, co-founder and CTO of Tierra Climate, joins the Houston Innovators Podcast. Photo via LinkedIn

If the energy transition is going to be successful, the energy storage space needs to be equipped to support both the increased volume of energy needed and new energies. And Emma Konet and her software company, Tierra Climate, are targeting one part of the equation: the market.

"To me, it's very clear that we need to build a lot of energy storage in order to transition the grid," Konet says on the Houston Innovators Podcast. "The problems that I saw were really on the market side of things." Read more.

Cindy Taff, CEO of Sage Geosystems

Houston-based Sage Geosystems announced the first close of $17 million round led by Chesapeake Energy Corp. Photo courtesy of Sage

A Houston geothermal startup has announced the close of its series A round of funding.

Houston-based Sage Geosystems announced the first close of $17 million round led by Chesapeake Energy Corp. The proceeds aim to fund its first commercial geopressured geothermal system facility, which will be built in Texas in Q4 of 2024. According to the company, the facility will be the first of its kind.

“The first close of our Series A funding and our commercial facility are significant milestones in our mission to make geopressured geothermal system technologies a reality,” Cindy Taff, CEO of Sage Geosystems, says. Read more.

Clemmie Martin, chief of staff at The Cannon

With seven locations across the Houston area, The Cannon's digital technology allows its members a streamlined connection. Photo courtesy of The Cannon

After collaborating over the years, The Cannon has acquired a Houston startup's digital platform technology to become a "physical-digital hybrid" community.

Village Insights, a Houston startup, worked with The Cannon to create and launch its digital community platform Cannon Connect. Now, The Cannon has officially acquired the business. The terms of the deal were not disclosed.

“The integration of a world-class onsite member experience and Cannon Connect’s superior virtual resource network creates a seamless, streamlined environment for member organizations,” Clemmie Martin, The Cannon’s newly appointed chief of staff, says in the release. “Cannon Connect and this acquisition have paved new pathways to access and success for all.” Read more.

Texas organization grants $68.5M to Houston institutions for recruitment, research

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.”

He also is co-founder and former CEO of Xilis, a Durham, North Carolina-based oncology therapy startup that raised $70 million in series A funding in 2021. Before joining the institute in 2021, the Stanford University graduate was an associate professor at Duke University in Durham.

Shen and Xilis aren’t strangers to MD Anderson.

In 2023, MD Anderson said it planned to use Xilis’ propriety MicroOrganoSphere (MOS) technology for development of novel cancer therapies.

“Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current … models, which we hope will bring medicines to patients more quickly,” Shen said in an MD Anderson news release.

Here are the two other Cancer Prevention and Research Institute of Texas (CPRIT) awards that will bring noted cancer researchers to Houston:

  • $4 million to attract David Sarlah to Rice University from the University of Illinois, where he is an associate professor of chemistry. Sarlah’s work includes applying the principles of chemistry to creation of new cancer therapies.
  • $2 million to lure Vishnu Dileep to the Baylor College of Medicine from the Massachusetts Institute of Technology (MIT), where he is a postdoctoral fellow. His work includes the study of cancer genomes.

CPRIT also handed out more than $56.5 million in grants and awards to seven institutions in the Houston area. Here’s the rundown:

  • MD Anderson Cancer Center — Nearly $25.6 million
  • Baylor College of Medicine — Nearly $11.5 million
  • University of Texas Health Science Center at Houston — More than $6 million
  • Rice University — $4 million
  • University of Texas Medical Branch at Galveston — More than $3.5 million
  • Methodist Hospital Research Institute — More than $3.3 million
  • University of Houston — $1.4 million

Dr. Pavan Reddy, a CPRIT scholar who is a professor at the Baylor College of Medicine and director of its Dan L Duncan Comprehensive Cancer Care Center, says the CPRIT funding “will help our investigators take chances and explore bold ideas to make innovative discoveries.”

The Houston-area funding was part of nearly $99 million in grants and awards that CPRIT recently approved.